Advertisement

Topics

FDA Should Let Alzheimer’s Trials Rely On Single Endpoint, Group Says

14:12 EDT 17 May 2017 | SCRIP

Informally, FDA appears open to trials that use cognition as the only primary endpoint rather than insisting that products also...

      

Related Stories

 

Original Article: FDA Should Let Alzheimer’s Trials Rely On Single Endpoint, Group Says

NEXT ARTICLE

More From BioPortfolio on "FDA Should Let Alzheimer’s Trials Rely On Single Endpoint, Group Says"

Quick Search
Advertisement
 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...